References
- Burzykowski T, Molenberghs G, Buyse M (2001). Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. J Roy Stat Soc C Appl Stat, 50, 405-22. https://doi.org/10.1111/1467-9876.00244
- Buyse M, Burzykowski T, Carroll K, et al (2007). Progressionfree survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol, 25, 5218-24. https://doi.org/10.1200/JCO.2007.11.8836
- Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al (2008). Evaluation of tumor response, disease control, progressionfree survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol, 26, 1987-92. https://doi.org/10.1200/JCO.2007.10.8407
- Coiffier B, Gisselbrecht C, Vose JM, et al (1991). Prognostic factors in aggressive malignant lymphomas. Description and validation of prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol, 9, 211-19. https://doi.org/10.1200/JCO.1991.9.2.211
- Collette L, Burzykowski T, Carroll KJ, et al (2005). Is prostatespecific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? J Clin Oncol, 23, 6139-48. https://doi.org/10.1200/JCO.2005.08.156
- de Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. J Clin Oncol, 18, 2938-47. https://doi.org/10.1200/JCO.2000.18.16.2938
- Dimopoulos MA, Barlogie B, Smith TL, et al (1991). High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med, 115, 931-35. https://doi.org/10.7326/0003-4819-115-12-931
- Donskov F, von der Maase H (2006). Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol, 24, 1997-05. https://doi.org/10.1200/JCO.2005.03.9594
- Ferrara N, Hillan KJ, Gerber HP, et al (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391. https://doi.org/10.1038/nrd1381
- Ferrara N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25, 581-?. https://doi.org/10.1210/er.2003-0027
- Grothey A, Hedrick EE, Mass RD, et al (2008). Responseindependent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol, 26, 183-89. https://doi.org/10.1200/JCO.2007.13.8099
- Hecht JR, Trarbach T, Jaeger E (2005). A randomized, doubleblind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5- fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol, 23, 16S (abstr LBA3).
- Heng DY, Xie W, Regan MM, et al (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factortargeted agents:results from a large, multicenter study. J Clin Oncol, 27, 5794-99. https://doi.org/10.1200/JCO.2008.21.4809
- Hollen CW, Henthorn J, Koziol JA, et al (1992). Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma, 8, 235-41. https://doi.org/10.3109/10428199209054910
- Kemeny N, Braun DW Jr (1983). Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med, 74, 786-94. https://doi.org/10.1016/0002-9343(83)91066-5
- Kerbel RS, Kamen BA (2004). The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer, 4, 423-?. https://doi.org/10.1038/nrc1369
- Mancuso P, Colleoni M, Calleri A, et al (2006). Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 108, 452-?. https://doi.org/10.1182/blood-2005-11-4570
- Nisman B, Barak V, Hubert A, et al (2003). Prognostic factors for survival in metastatic breast cancer during first line paclitaxel chemotherapy. Anticancer Res, 23, 1939-42.
- Saltz L, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 343, 905-14. https://doi.org/10.1056/NEJM200009283431302
- Suppiah R, Shaheen PE, Elson P, et al (2006). Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer, 107, 1793-00. https://doi.org/10.1002/cncr.22237
- Tas F, Aykan F, Alici S, et al (2001). Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol, 24, 547-50. https://doi.org/10.1097/00000421-200112000-00003
- Tas F, Aydiner A, Demir C, et al (2001). Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer. Am J Clin Oncol, 24, 376-78. https://doi.org/10.1097/00000421-200108000-00013
- Tournigand C, Andre T, Achille E, et al (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22, 229-37. https://doi.org/10.1200/JCO.2004.05.113
- Tournigand C, Cervantes A, Figer A, et al (2006). OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol, 24, 394-00. https://doi.org/10.1200/JCO.2005.03.0106
Cited by
- Biomarkers for Anti-Angiogenic Therapy in Cancer vol.14, pp.5, 2013, https://doi.org/10.3390/ijms14059338
- Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0134732
- Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact vol.10, pp.9, 2015, https://doi.org/10.1371/journal.pone.0136752
- XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10375
- Diet and Colorectal Cancer Risk in Asia - a Systematic Review vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5389
- Analyses of Multiple Factors for Determination of "Selected Patients" Who Should Receive Rechallenge Treatment in Metastatic Colorectal Cancer: a Retrospective Study from Turkey vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2833
- Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy vol.30, pp.8, 2015, https://doi.org/10.1007/s00384-015-2264-0
- Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients vol.32, pp.2, 2015, https://doi.org/10.1007/s12032-014-0456-z
- Study of Perpheral Neutrophil to Lymphocyte Ratio (NLR) in Different Stages Prognosis of Colorectal Cancer vol.05, pp.02, 2016, https://doi.org/10.12677/ACRPO.2016.52003
- The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2276-3
- Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer vol.108, pp.3, 2013, https://doi.org/10.1038/bjc.2012.545
- Checkpoint inhibition for colorectal cancer: progress and possibilities vol.8, pp.6, 2016, https://doi.org/10.2217/imt-2016-0013
- Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway vol.19, pp.4, 2018, https://doi.org/10.3390/ijms19041232